Clinical Trial Detail

NCT ID NCT03092323
Title A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Alliance for Research through Collaboration
Indications

malignant fibrous histiocytoma

pleomorphic liposarcoma

sarcoma

fibrosarcoma

spindle cell sarcoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.